The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 6, 1997, Pages 546-551

  Hupperets, Pierre S G J ^a,b   Volovics, Lex ^a,c   Schouten, Leo J ^a   Jager, Jos J ^a,d   Schouten, Harry C ^a,b   Hillen, Harry F ^a   Blijham, Geert H ^a,e  

^a Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRO CLINIC   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; Node positive; Prognostic significance; Steroid receptor content

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; RISK ASSESSMENT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 0030664188     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199712000-00002     Document Type: Article

References (51)

1. Knight WA III, Livingstone RB, Gregory EG, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37:4669-71.
2. Rich MA, Furmanski P, Brooks SC, and the Breast Cancer Prognostic Study Surgery and Pathology Associates. Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res 1978;38:4296-8.
3. Mayhard PV, Blarney RW, Elston CW, et al. Estrogen receptor assay in primary breast cancer and early recurrence of disease. Cancer Res 1978;33:4292-5.
4. Allegra JC, Lippman ME, Simon R, et al. Association between steroid hormone receptor status and disease free survival in breast cancer. Cancer Treat Res 1979;63:1271-7.
5. Cooke T, George D, Shields R, et al. Oestrogen receptors and prognosis in early breast cancer. Lancet 1979;ii:995-7.
6. Osborne CK, Yochmowitz MG, Knight WA III, et al.. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
7. Westerberg H, Gustafson SA, Nordenskjöld B, et al. Estrogen receptor level and other factors in early recurrence of breast cancer, Int J Cancer 1980;26:429-33.
8. Blarney RW, Bishop HM, Blake JRS, et al. Relationship between primary breast cancer tumor receptor status and patient survival. Cancer 1980;46:2765-9.
9. Gapinsky PV, Donegan WL. Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 1980; 88:386-93.
10. Valagussa P, DiFronzo G, Bignami P, et al. Prognostic importance of estrogen receptors to select node-negative patients for adjuvant chemotherapy. In: Salmon SE, Jones SE,eds. Adjuvant Therapy in Cancer III. New York: Grune & Stratton 1981:329-33.
11. Samaan NA, Buzdar Ak, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554-60.
12. Kinne DW, Ashikari R, Butler A, et al. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 1981; 47:2364-7.
13. Godolphin W, Elwood JM, Spinelli JJ. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int J Cancer 1981; 28:677-83.
14. Crowe JP, Hubay CA, Pearson DH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982;2:171-6.
15. Neifeld JP, Lawrence W Jr, Brown PW, et al. Estrogen receptors in primary breast cancer. Arch Surg 1982;25:581-4.
16. Paterson AHG, Zuck VP, Szafran O, et al. Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol 1982;18:937-43.
17. Logan LA, Cripps MC, Hirte WE, et al. The estrogen receptor test: a prognostic tool in primary breast cancer. Can J Surg 1982;25:581-4.
18. Alanko A, Heinonen E, Scheinin T, et al. Significance of estrogen and progesterone receptors, disease free survival and site of metastases on survival of breast cancer patients. Cancer 1985;56:1696-700.
19. Pearson OH, Hubay CA, Gordon NH, et al. Estrogen receptors and prognosis in breast cancer. In: Hormonally Responsive Tumors. New York: Academic Press 1985:487-503.
20. McGuire WL, Clark GM, Dressier LG, et al. Role of steroid hormone receptors as prognostic factors in primary breast cancer. Monogr Natl Cancer Inst 1986;1:19-23.
21. McGuire WL. Prognostic factors in primary breast cancer. Cancer Surv 1986;5:527-36.
22. Kallioniemi OP, Blanco G, Alavaikko M, et al. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987;56:637-42.
23. Williams MR, Todd JH, Ellis IO, et al. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987;55:67-73.
24. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Protocol B-06. J Clin Oncol 1988;6:1076-87.
25. Chevallier B, Heintzmann F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Cancer 1988;62:2517-24.
26. Sigurdsson H, Badetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-53.
27. Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979;44:671-5.
28. Furmanski P, Saunders DE, Brooks SC, et al. The prognostic value of estrogen determinations in patients with primary breast cancer: an update. Cancer 1980;46:2794-6.
29. von Maillot K, Horke W, Prestele H. Prognostic significance of steroid receptor content in primary breast cancer. Arch Gynaecol 1982;231:185-90.
30. Howat JMT, Barnes DM, Harris M, Swindell R. The association of cytosol estrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 1983;47:629-40.
31. Saez S, Cheix F, Asselain B. Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat 1983;3:345-54.
32. Raemaekers JMM, Beex LVAM, Koenders AJM, et al. Disease free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: an analysis after long-term follow-up. Breast Cancer Res Treat 1985;6:123-30.
33. Todd JH, Dowle CS, Williams WR, et al. Conformation of a prognostic index in breast cancer. Br J Cancer 1987;56:482-92.
34. Clark GM, Dressier LG, Owens MA, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.
35. Pichon MF, Pallud C, Brunet M, et al. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 1980;40:3357-60.
36. Clark GM, McGuire WL, Hubay CA, et al. Progesterone receptor as a prognostic factor in stgae II breast cancer. N Engl J Med 1983;309:1343-7.
37. Thorpe SH, Rose C, Rasmussen BB, et al. Prognostic value of steroid receptors: multivariate analysis of systematically untreated patients with node-negative primary breast cancer. Cancer Res 1987;47:6126-33.
38. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-72.
39. Mason BH, Holdaway IM, Mullins RR, et al. Progesterone and estrogen receptor as prognostic variables in breast cancer. Cancer Res 1983;43:2985-90.
40. Di Fronzo G, Cappaletti V, Coradini D, et al. Prognostic significance of progesterone receptors alone in association with estrogen receptors in human breast cancer. Tumori 1984;70:159-64.
41. Kohail HH, Elias EG, El-Nowiem SA, et al. A multifactorial analysis of steroid hormone receptors in stage I and II breast cancer. Ann Surg 1985;201:611-7.
42. Fisher B, Redmond CK, Wickerman DL, et al. Rrelation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant therapy. Breast Cancer Res Treat 1983;3:355-65.
43. Howell A, George WD, Crowther D, et al. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for breast Cancer. Lancet 1982:ii:307-11.
44. Raemaekers JJM, Beex LVAM, Pieters GFFM. et al. Progesterone receptor activity and the relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy. Breast Cancer Res Treat 1987;9:191-9.
45. Thorpe SM, Christensen IJ, Rasmussen BB, et al. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 1993;29A:971-7.
46. Hupperets PSGJ, Wils J, Volovics Let al. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol 1993;4:295-301.
47. Brown M. Estrogen receptor molecular biology. Hematol Oncol Clin North Am 1994;8:101-12.
48. Hill SM, Fuqua SAW, Chamness GC, et al. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 1989;49:145-8.
49. McGuire WL, Chamness CG, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-7.
50. Hedley DW. Flow cytometry using paraffin-embedded tissue: five years on. Cytometry 1989;10:229-41.
51. Vindeløv LL. Christensen U, Nissen NI. A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.